Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 11:18:15 Source:travelViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:The bodies of 4 men and 2 women were found strangled, piled up in Mexican resort of Acapulco
Next:Saints open voluntary practice without Marshon Lattimore or Alvin Kamara
You may also like
- Time's up after 3 hours as NFL limits interviews for coaches still busy in playoffs
- Alaska budget negotiators announce tentative deal as legislative session nears deadline
- MAUREEN CALLAHAN: It's the Me
- Wife is spared jail for stabbing her husband for falling asleep while she was talking to him
- Yemen's Iran
- Alice Munro, Nobel literature winner revered as short story master, dead at 92
- Ontario will suspend driver’s licenses for convicted car thieves for at least 10 years
- Messi the dog comes to Cannes for an encore
- Daniel Cuvet hits a pair of three